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Background To examine mild cognitive impairment and its associations with subclinical cardiac dysfunction in patients with
chronic heart disease yet to develop the clinical syndrome of chronic heart failure (CHF).
...................................................................................................................................................................................................
Methods
and results
Patients from the Nurse-led Intervention for Less Chronic Heart Failure Study (n = 373 with chronic heart disease
other than CHF; 64 ± 11 years, 69% men) were screened for mild cognitive impairment [Montreal cognitive assessment
(MoCA) score <26] and underwent echocardiographic/clinical profiling. We investigated associations of mild cognitive
impairment and MoCA cognitive domain subscores with global cardiac status (‘normal’ vs. ‘diastolic dysfunction’ vs.
‘other cardiac abnormality’) and individual echocardiographic parameters. Patients with mild cognitive impairment (n =
161; 43%) demonstrated a higher age-adjusted prevalence of diastolic dysfunction (37% vs. 24%; P < 0.05). Multivariate
logistic regression (adjusted for age, sex, and other relevant clinical factors) indicated that the odds of mild cognitive
impairment were two-times higher with diastolic dysfunction (P = 0.030) and 1.7-times higher with ‘other cardiac abnor-
malities’ (P = 0.082) vs. normal cardiac status. In turn, mild cognitive impairment was predicted by left-ventricular (LV)
filling pressure (based on the ratio of early diastolic filling and annular velocities; adjusted odds ratio 1.07 per unit
increase, P = 0.022), but not LV structural parameters. Specific deficits in the cognitive domains of executive functioning
and visuo-constructional abilities were also independently predicted by diastolic dysfunction (P < 0.05).
...................................................................................................................................................................................................
Conclusion Mild cognitive impairment is prevalent in patients with subclinical chronic heart disease at high-risk of CHF.
Independent associations with LV diastolic dysfunction suggest a link between cardiac and cognitive functioning
beyond shared risk factors.
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Introduction
Advancements in cardiovascular prevention and management con-
tinue to improve survival and progressively shift the burden of disease
toward comorbidities such as cognitive impairment. Even mild cogni-
tive impairment (MCI)—defined by deficits in objectively assessed
cognitive function but no apparent impact on activities of daily liv-
ing—is associated with reduced quality of life and poor prognosis
(including dementia and death).1,2 Notwithstanding its clinical impor-
tance, MCI continues to be under-recognized and under-treated.
Chronic heart disease—particularly in an advanced form sufficient
to cause the clinical syndrome of heart failure (CHF)—is now widely
recognized as an antecedent of MCI.2,3 However, the disproportion-
ately high prevalence of MCI with key CHF predecessors (e.g. coro-
nary artery disease, atrial fibrillation, hypertension and type 2
diabetes)4 points to cognition also being affected during the evolution
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of CHF. In this context of subclinical (i.e. asymptomatic) disease, MCI
may reflect the consequences of distinct cardiac structural and/or
functional abnormalities readily detectable from echocardiography
and/or other non-invasive imaging modalities.5 Several studies have
indeed reported on the predictive capacity of broad-based haemody-
namic factors (e.g. cardiac output) for cognitive function6,7; however,
compensatory mechanisms tend to maintain these parameters within
a normal range until the onset of relatively advanced CHF. Thus, in
the setting of subclinical disease, cardiac involvement in MCI is more
likely to reflect early manifestations of left-ventricular (LV) impair-
ment such as LV hypertrophy and/or diastolic dysfunction. However,
these factors have only been investigated at the population level, with
inconsistent results.8,9
In the present study, we examined MCI in the Nurse-led
Intervention for Less Chronic Heart Failure (NIL-CHF) Study—a trial
directed at prevention of clinical CHF in high-risk individuals.10
Specifically, we sought the prevalence of MCI [measured via the
Montreal Cognitive Assessment (MoCA) tool]11 and its associations
with echocardiographically determined cardiac structure and func-
tion (particularly LV geometry and diastolic function).
Methods
Study cohort
Detailed methods for the NIL-CHF Study (Australian New Zealand
Clinical Trials Registry No. 12608000022369) have been described previ-
ously.10,12 The trial was designed to evaluate an intervention to prevent
clinical CHF in high-risk individuals during 3–5 years follow-up. Briefly,
cardiac inpatients at an Australian tertiary referral hospital were eligible
for enrolment if they were aged >_45 years and were hospitalized with
chronic heart disease but without evidence of clinical CHF. Congenital
conditions, significant valve disease, terminal malignancy, or subsequent
acute cardiac events within 30 days of hospital discharge (including acute
heart failure), mandated exclusion from the study. Of 611 patients com-
prising the NIL-CHF Study intention-to-treat population, 454 (all English-
speaking and without clinical CHF or asymptomatic systolic dysfunction
at the time of examination) completed the MoCA, underwent echocar-
diographic examination for cardiac function, and were clinically profiled.
Exclusion of patients with cerebrovascular disease (n= 81) left a final
study cohort of n= 373. Data for 298 of these patients were taken from
the baseline assessment performed one-month post-hospital discharge,
with the remaining 75 patients’ data collected at 36-month follow-up.
The study was approved by the Alfred Hospital Human Research Ethics
Committee and all patients provided written informed consent.
Clinical profiling
Standard demographic and clinical data were recorded at study entry
(including age, sex, education level, medical history, and current medication
regimen). The comprehensive cardiovascular assessment included body
mass index (BMI), blood pressure (BP), blood biochemistry (by standard
hospital pathology protocols) and lifestyle factors (i.e. smoking history and
alcohol intake frequency—categorized as low [<once-weekly], moderate
[1–4 days/week] or high [>_5 times/week]). Hypertension was defined as
BP >_140/90 mmHg and/or use of antihypertensive medication. The
International Physical Activity Questionnaire13 was administered to quantify
physical activity (low being <600 metabolic equivalent (MET)-minutes/
week; moderate 600–1499 MET-min/week; high >_1500 MET-min/week).
Saturated fat intake was assessed using a validated dietary survey, with ‘poor
dietary habits’ reflecting non-compliance with a National Cholesterol
Education Program Adult Treatment Panel III-recommended Therapeutic
Lifestyle Changes diet.14 Presence of depressive symptoms was determined
from the Centre for Epidemiologic Studies Depression scale15 subsequent
to a positive response to Arroll’s depression screening questions.16
Echocardiography
Standard 2D resting echocardiography was performed in the lateral decu-
bitus position using a GE Vivid i ultrasound system (GE Healthcare,
Chicago, USA) equipped with a 3.5 MHz (3S-RS) transducer. All volume-
based measurements were indexed to body surface area. Stroke volume
and cardiac output were derived from pulsed-wave Doppler of the LV
outflow tract. LV ejection fraction was calculated from LV end-diastolic
and end-systolic volumes (modified Simpson’s method [91%], or—in
case of inadequate image quality—M-mode [cubed method; 5%], or vis-
ual/‘eyeball’ assessment [4%]). Left-atrial (LA) end-diastolic volume was
calculated using the area-length method (subgroup of 315 patients only
[84%]). LV mass index was calculated from the LV internal dimension and
wall thicknesses according to the formula recommended by the
European Association of Echocardiography/American Society of
Echocardiography.17 Mitral inflow was characterized using pulsed-wave
Doppler, from which the early diastolic filling (E) and septal annular (e0)
velocities were derived. The ratio of E/e0 was calculated as a surrogate of
LV filling pressure. Finally, scans of the right and left common carotid
arteries (patient positioned supine; using a 12L-RS broadband linear array
transducer [5–13 MHz]) enabled measurement of the mean intima-media
thickness (IMT)—an indicator of atherosclerotic burden and potentially
important covariate4—in a subgroup of 349 patients (94%).
Characterization of cardiac structure/
function
Global cardiac status was categorized as follows10:
i. No evidence of a cardiac abnormality (‘Normal’)
ii. ‘Diastolic dysfunction’ based on mitral inflow consistent with a
pseudo-normalization pattern, or mild diastolic dysfunction with
E/e0 >_15 (adjudicated per guidelines18; excluding indeterminate cases)
iii. any ‘other cardiac abnormality’, including: (a) LV hypertrophy based
on LV mass; (b) septal or posterior wall thickening (>1.1 cm); (c)
mild-moderate valvular dysfunction; and (d) possible (but indetermi-
nate) diastolic dysfunction
In addition to the global cardiac status categories, the following individ-
ual structural and functional parameters were analysed: (i) LV hypertro-
phy (LV mass index >_102 g/m2 [men] and >_88 g/m2 [women])17; (ii) LA
enlargement (i.e. LA volume index >_34 mL/m2); (iii) LV filling pressure
estimated by E/e0 (where <_8 = normal, 8–15 = indeterminate, >_15 = ele-
vated)18; and (iv) elevated LV filling pressure estimated from both E/e0
and LA volume index (i.e. E/e0 ratio >_15 or >8 with concurrent LA
enlargement). Analyses involving variables derived from LA volume were
restricted to the 315 patients (84%) with available data.
Assessment of cognitive function
The MoCA is a validated one-page screening tool for MCI that was com-
pleted in-person by trained personnel.11 It assesses a number of cognitive
domains: short-term and working memory, visuoconstructional abilities,
executive functioning, sustained attention and concentration, language
abilities, and orientation. The total score out of 30—to which one point
is added for <_12 years formal education—reflects global cognition. MCI
was indicated by a score <26.11 Deficits in each of the six constituent
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cognitive domains were defined by the relevant MoCA subscore
being <100%.
Statistical analyses
Analyses were undertaken using IBM SPSS Statistics version 22.0 (IBM
Corp, Armonk, NY, USA). Unless otherwise specified, missing data for all
variables was <5% and P<0.05 defined statistical significance. Continuous
variables were expressed as mean ± standard deviation (SD) or median
with interquartile range, depending on normality of distribution
(Kolmogorov–Smirnov test). Categorical data were expressed as percen-
tages. Group comparisons of continuous and categorical variables were
performed using unpaired t- and v2-tests, respectively. Where adjust-
ment for covariate(s) was required, analysis of covariance (ANCOVA;
continuous variables) or binary/multinomial logistic regression (categori-
cal variables) were applied.
Multivariate logistic regression (enter method) was used to examine
independent associations of cardiac structure/function with MCI. An ini-
tial model featuring global cardiac status (i.e. ‘diastolic dysfunction’ and
‘other cardiac abnormality’ categories vs. ‘normal’) was considered the
primary analysis. This was based on: (i) enabling of a direct comparison of
the adjusted odds of MCI in the presence of functional, as opposed to
structural abnormalities; and (ii) global cardiac status being considered
the most robust indicator of subclinical cardiac disease given its integra-
tion of multiple echocardiographic parameters. Secondary analyses
sought associations between MCI and individual echocardiographic
parameters (separate models for each to avoid collinearity).
Results
MCI was identified in 161 patients (43% of the cohort) and subclinical
cardiac disease in 260 patients (70% of the cohort; 109 [29%] with dia-
stolic dysfunction and 151 [41%] an ‘other cardiac abnormality’).
Clinical characteristics according to MCI status are displayed in Table 1.
Since those with MCI were older, comparisons of other variables were
made with and without age-adjustment. The presence of MCI was
characterized by more prevalent depressive symptoms, smoking, and
poor dietary habits, less frequent alcohol consumption, and higher car-
otid IMT (where each of these group differences remained at least bor-
derline significant after age-adjustment). The higher rate of atrial
fibrillation in patients with MCI, along with their lower BMI and diastolic
BP (and corresponding higher pulse pressure) became non-significant
after age-adjustment.
MCI and global cardiac status (primary
analysis)
In the primary multiple logistic regression model, the following cova-
riates were entered alongside global cardiac status: age, sex, and edu-
cation, variables found to be associated with MCI independent of age
(i.e. depressive symptoms, smoking, poor dietary habits, and alcohol
consumption—per Table 1) and other factors with recognized rela-
tionships to cognitive function (i.e. diabetes,19 atrial fibrillation20 and
associated therapy,21 physical activity,22 and pulse pressure23). With
respect to atrial fibrillation therapy, we favoured model adjustment
for anticoagulation since it predicted MCI and resulted in a better
model fit compared with adjustment for antiplatelet or antithrom-
botic (i.e. composite of antiplatelet and/or anticoagulation) therapy.
In addition, we collapsed the physical activity categories of ‘moderate’
and ‘high’ into a binary variable since this also improved model fit.
As shown in Figure 1, both diastolic dysfunction and other cardiac
abnormalities (vs. normal) were independently associated with
MCI—the latter being borderline significant.
Concurrent predictors of MCI were older age, atrial fibrillation,
smoking, poor dietary habit (all P< 0.05) and depressive symptoms
(trend only; P= 0.073). Anticoagulant therapy and moderate alcohol
intake demonstrated borderline significant reduced odds of MCI. In
subsequent sensitivity analyses, additional adjustment for coronary
artery disease, BMI, MAP, and carotid IMT did not substantively
impact results (data not shown).
MCI and specific cardiac structural/
functional markers
Echocardiographic parameters according to MCI status are displayed
in Table 2 (with and without age-adjustment). The predictive capacity
of these parameters for MCI (with and without adjustment for the
same covariates outlined in the primary analysis) is reported in Table 3.
Cardiac structure
Consistent with the higher prevalence of ‘other cardiac abnormal-
ities’ relative to ‘Normal’, patients with MCI demonstrated signifi-
cantly greater relative wall thickness and a trend toward higher LV
mass index; however, on an age-adjusted basis, none of these group
differences were significant (Table 2). In the fully-adjusted prediction
models (Table 3), no associations were apparent between MCI and
LV hypertrophy; nor LV mass index and relative wall thickness
expressed as continuous variables.
Cardiac diastolic function
Poorer values for all individual diastolic functional markers (i.e. e0,
E/e0, LA volume index, and derived markers of LV filling pressure)
were observed in the group with MCI (Table 2). With the exception
of E/e0 (when expressed categorically) and e0 itself, these differences
appeared largely independent of age (i.e. at least borderline significant
post-adjustment). With full adjustment (Table 3), E/e0 expressed as a
continuous variable independently predicted MCI. When analysed as
a categorical variable, elevated E/e0 (>_15) vs. normal E/e0 (<_8) was a
borderline significant predictor. In contrast, the univariate association
of MCI with e0 was attenuated and became non-significant following
covariate adjustment; likewise LA volume index and derived markers
of LV filling pressure.
Associations of cardiac structure/
function with deficits in specific cognitive
domains
The proportions of patients with deficits in specific cognitive domains
are displayed in Figure 2. Short-term/working memory was affected in
the majority of the cohort (regardless of MCI). The next most com-
monly observed impairments were in executive functioning and
visuoconstructional abilities (>70% of patients with MCI vs. <50%
without MCI). Conversely, orientation domain scores indicated
largely preserved function (deficit rate <20% in each group).
Of the six MoCA domains, global cardiac status was related to def-
icits in executive functioning (v2, P= 0.002) and visuoconstructional
abilities (v2, P= 0.009), but not to language ability, short-term/
working memory, sustained attention/concentration, or orientation.
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Diastolic dysfunction was a predictor of deficits in both executive
functioning and visuoconstructional abilities (i.e. unadjusted, as well
as in multivariate analyses featuring the same covariates described for
aforementioned MCI prediction models; Figure 1). In contrast, classifi-
cation in the ‘other cardiac abnormality’ category predicted a visuo-
constructional ability deficit, but was unrelated to executive
functioning. E/e0 expressed as a continuous variable was an
independent predictor of executive functioning, but not visuocon-
structional ability.
Discussion
To our knowledge, this is the first report linking diastolic dysfunction
with MCI in patients with subclinical chronic heart disease at high-risk
of developing the clinical CHF syndrome. We found that the
....................................................................................................................................................................................................................
Table 1 Clinical characteristics of the study cohort by MCI status
MCI
(n5 161)
No MCI
(n5 212)
P P (age-adjusted)
Age (years) 67 ± 12 62 ± 9 <0.001
Male (%) 71 68 0.55
Education <_12 years (%) 47 42 0.27
Living alone (%) 41 39 0.72
Clinical profile (%) Coronary artery disease 73 68 0.30 0.24
Peripheral artery disease 14 11 0.32 0.998
Diabetes 25 24 0.86 0.84
Hypertension 91 93 0.56 0.38
Atrial fibrillation 19 10 0.015 0.17
Chronic kidney disease 17 11 0.075 0.997
Cancer 16 10 0.14 0.60
Depressive symptoms 29 18 0.010 0.001
Lifestyle risk factors (%) Smoking 26 15 0.012 <0.001
Physical activity 0.37 0.63
Low 56 49
Moderate 21 23
High 24 28
Poor dietary habit 39 24 0.002 <0.001
Alcohol intake frequency 0.033 0.060
Low 57 43
Moderate 24 33
High 19 24
Clinical measures Body mass index (kg/m2) 27.7 (24.5–31.1) 27.9 (25.3–32.4) 0.042a 0.21a
Systolic BP (mmHg) 134 ± 19 133 ± 17 0.59 0.91
Diastolic BP (mmHg) 74 ± 12 76 ± 12 0.040 0.50
Pulse pressure (mmHg) 59 (50–71) 56 (48–66) 0.035a 0.89a
MAP (mmHg) 94 ± 12 95 ± 12 0.29 0.64
Total cholesterol (mmol/L) 3.9 (3.2–4.8) 3.9 (3.2–4.7) 0.81a 0.69a
Medical therapy (%) Antithrombotic 76 80 0.36 0.26
Antiplatelet 69 71 0.63 0.74
Anticoagulant 12 14 0.72 0.18
Statin 68 73 0.36 0.42
ACE or ARB 70 72 0.75 0.48
b-Blocker 47 51 0.53 0.56
Calcium channel blocker 24 22 0.64 0.97
Diuretic 15 9 0.075 0.38
Digoxin 7 3 0.066 0.35
Carotid intima-media thickness (mm) 0.73 (0.63–0.86) 0.67 (0.58–0.76) <0.001a 0.029a
Data are mean ± standard deviation, median (interquartile range), or % (unadjusted). P-values reflect t-test or v2. Age-adjusted P-values are based on analysis of covariance
(continuous variables) or binary/multinomial logistic regression (categorical variables).
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BP, blood pressure; MAP, mean arterial pressure; MCI, mild cognitive impairment.
aIndicates log-transformed data used for t-test/analysis of covariance (due to skewed distribution).
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..prevalence of MCI was relatively high (43%) in this setting. In turn,
those with evidence of LV diastolic dysfunction based on sensitive
echocardiographic markers demonstrated odds of concurrent MCI
that were approximately two-times higher than for individuals with
normal cardiac function, even after adjustment for age, sex, and other
relevant clinical covariates. Collectively, these findings suggest links
between cardiac and cognitive function not only with advanced dis-
ease associated with impairment of cardiac haemodynamics, but also
at earlier, subclinical stages within the evolution of CHF.
Cognitive impairment in cardiac disease
Cognitive screening with the MoCA tool indicated MCI in almost half
of the current cohort. This should be generalizable to the broader
subclinical CHF population given our study’s relatively unrestrictive
eligibility criteria. Indeed, reported prevalence is likely to be conser-
vative given that patients with cerebrovascular disease and systolic
dysfunction were excluded. That MCI is a more frequent finding in
those at risk of clinical CHF compared with the general older popula-
tion (where prevalence estimates span 10–20% in those >65 years),1
is not unexpected given previous reports of poorer cognitive func-
tion in association with individual CHF antecedents on which enrol-
ment in the NIL-CHF study was based (i.e. coronary artery disease,3
hypertension,4 type 2 diabetes,19 and atrial fibrillation20).
Comparison of the clinical profiles of patients with and without MCI
demonstrated similar burdens of these comorbidities except for
atrial fibrillation, which was more common in patients with MCI.
Notably, lifestyle-related risk factors (i.e. smoking, diet, and alcohol
intake) were more disparate between groups.
Figure 1 Prediction of MCI by global cardiac status (primary anal-
ysis). The multivariate logistic regression model (enter method) was
adjusted for age, sex, education <_12 years, atrial fibrillation, anticoa-
gulant therapy, diabetes, depressive symptoms, smoking, poor diet-
ary habit, physical activity, alcohol intake, and pulse pressure. CI,
confidence interval.
....................................................................................................................................................................................................................
Table 2 Cardiac structure/function in patients with and without MCI
MCI (n5 161) No MCI (n5 212) P P (age-adjusted)
Global cardiac status (%) 0.002 0.047
Normal 22 37
Other cardiac abnormality 42 40 0.028 0.10
Diastolic dysfunction 37 24 0.001 0.015
Stroke volume index (mL/m2) 40 (35–45) 38 (33–45) 0.30a 0.66a
Cardiac index (L/min/m2) 2.4 (2.1–2.9) 2.4 (2.0–2.8) 0.10a 0.23a
Ejection fraction (%) 63 ± 7 64 ± 7 0.16 0.24
Fractional shortening (%) 35 (33–38) 36 (32–39) 0.40a 0.71a
Cardiac structure
LV mass index (g/m2) 92 ± 18 89 ± 18 0.096 0.32
LV hypertrophy (%) 38 27 0.032 0.26
Relative wall thickness 0.46 ± 0.09 0.44 ± 0.08 0.049 0.45
Cardiac (diastolic) function
e0 (cm/s) 6.5 ± 1.9 7.1 ± 2.0 0.008 0.82
E/e0 11.3 (8.8–15.4) 10.1 (8.1–12.9) <0.001a 0.069a
E/e0 category (%) 0.005 0.27
<_8 14 23
8–15 59 62 0.14 0.41
>_15 27 15 0.002 0.11
LA volume index (mL/m2)b 37 (31–41) 33 (29–39) 0.001a 0.027a
LA volume index >_34 mL/m2 (%)b 63 44 0.002 0.044
Elevated LV filling pressure (%)b 60 39 <0.001 0.051
Data are mean ± standard deviation, median (interquartile range), or % (unadjusted). P-values reflect t-test or v2. Age-adjusted P-values are based on analysis of covariance (con-
tinuous variables) or binary/multinomial logistic regression (categorical variables).
e0 , early diastolic septal annular velocity; E/e0 , ratio of early diastolic filling and septal annular velocities; LA, left-atrial; LV, left-ventricular; MCI, mild cognitive impairment.
aIndicates log-transformed data used for t-test/analysis of covariance (due to skewed distribution).
bLA volume measurements available in a subgroup only (n= 315; 84%).
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Deficits in specific cognitive domains in the current cohort were
most prevalent for short-term/working memory, followed by execu-
tive functioning and visuoconstructional abilities; however, relation-
ships with cardiac function were detected only for the latter two.
These findings are largely consistent with previous investigations of
cognitive function in cardiometabolic disease, which point to execu-
tive functioning—a domain with major implications for disease man-
agement—being particularly vulnerable to deterioration.3
Cognitive impairment and LV
dysfunction
Cognitive impairment is a widely recognized adjunct of clinical CHF
and several lines of evidence suggest that this reflects the haemody-
namic consequences of CHF, rather than shared risk profiles alone.
To date, this evidence has overwhelmingly come from studies in pre-
established clinical CHF associated with concurrent systolic dysfunc-
tion (i.e. reduced ejection fraction), which may coincide with cerebral
hypoperfusion and correlate with the severity of cognitive
decline.2,3,24 Perhaps for this reason, existing literature linking cogni-
tive impairment with specific cardiac characteristics—not just in
CHF, but also in population-based studies—has focused heavily on
markers mainly reflective of LV systolic function.3,5 Although diastolic
function and geometric factors were investigated in the Hoorn9 and
Southall and Brent Revisited (SABRE)8 cohorts, these were
population-based and thus inclusive of individuals with reduced ejec-
tion fraction (both symptomatic and subclinical). To our knowledge,
the current analysis is the first to address whether MCI is linked to
diastolic dysfunction, hypertrophy, and/or other early markers of LV
damage after removing the confounding haemodynamic consequen-
ces of systolic dysfunction. A key finding was the over-representation
of diastolic dysfunction in the subgroup with MCI. This association
was evident for diastolic dysfunction per se (i.e. primary analysis of
global cardiac status), as well as markers of LV filling pressure.
Importantly, both diastolic dysfunction and E/e0 predicted MCI inde-
pendently of relevant clinical covariates. This finding is significant in its
advocacy of diastolic dysfunction at least as a risk marker for MCI, but
potentially also as a risk factor and therapeutic target.
The predictive capacity of diastolic dysfunction for global MCI
appeared to primarily reflect associations with executive functioning
and visuoconstructional abilities (i.e. there was no relationship with
the domains of memory, attention, language or orientation). This is
largely concordant with the Hoorn study, in which LV diastolic
markers were related to executive functioning, but not memory.9 In
the SABRE cohort, diastolic dysfunction (classified as per the current
study) was unrelated to global and domain-specific indices of cogni-
tive function, though markers of LV filling pressure (E/e0 and LA
................................................................ ...............................................................
....................................................................................................................................................................................................................
Table 3 Independent prediction of MCI by specific cardiac markers
Univariate Multivariate*
n OR (95% CI) P n OR (95% CI) P
Cardiac structure
LV mass index, per 10 g/m2 365 1.10 (0.98–1.24) 0.096 363 1.02 (0.88–1.18) 0.80
Relative wall thickness, per 0.1 units 371 1.28 (1.00–1.64) 0.050 369 1.10 (0.83–1.46) 0.52
LV hypertrophy 365 1.62 (1.04–2.53) 0.033 363 1.31 (0.79–2.18) 0.30
Cardiac diastolic function
E/e0 (per unit) 373 1.08 (1.04–1.13) <0.001 371 1.07 (1.01–1.13) 0.022
E/e0 category
8–15 vs. <_8 373 1.53 (0.88–2.69) 0.14 371 1.42 (0.74–2.70) 0.29
>_15 vs. <_8 373 2.96 (1.50–5.82) 0.002 371 2.13 (0.92–4.96) 0.079
e0 (per 1 cm/s) 371 0.87 (0.78–0.97) 0.009 369 0.95 (0.83–1.10) 0.50
LA volume index (per 1 mL/m2) 315 1.04 (1.02–1.06) 0.001 314 1.02 (0.99–1.05) 0.14
LA volume index >_34 mL/m2 315 2.09 (1.32–3.31) 0.002 314 1.41 (0.82–2.43) 0.22
Elevated LV filling pressure 315 2.41 (1.52–3.82) <0.001 314 1.51 (0.85–2.69) 0.17
*Multivariate logistic regression models (enter method) were adjusted for age, sex, education <_12 years, atrial fibrillation, anticoagulant therapy, diabetes, depressive symptoms,
smoking, poor dietary habit, physical activity, alcohol intake, and pulse pressure (i.e. as per Figure 1).
CI, confidence interval; e0 , early diastolic septal annular velocity; E/e0 , ratio of early diastolic filling and septal annular velocities; LA, left-atrial; LV, left-ventricular; OR, odds ratio.
Figure 2 Proportion of patients with deficits in six cognitive
domains, according to global MCI status. P < 0.001 for MCI vs. no
MCI (for all). MCI, mild cognitive impairment.
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diameter) correlated with memory.8 Aside from methodological dif-
ferences between studies (particularly with respect to cognitive
assessment modality), we contend that these divergent findings prob-
ably reflect variation in the relative importance of diastolic function
for cognition across different clinical contexts.
Despite LV hypertrophy frequently coexisting with diastolic dys-
function, it contrarily demonstrated no significant relationship with
MCI. This result adds to a conflicting body of evidence pertaining to
LV mass and its relationship with cognition,9,25,26 which may reflect
between-study differences in patient population and extent of covari-
ate adjustment. Our exclusivity to subclinical CHF probably limited
our capacity to detect an association that may exist across a broader
range of disease severity.
Possible mechanisms
Since this study did not attempt to interrogate causality or mecha-
nisms, it must be acknowledged that—despite statistical adjustment
for a number of potential covariates—diastolic and cognitive decline
may simply represent parallel processes arising from a number of
shared risk factors. However, plausible links between diastolic dys-
function and MCI for future investigation include coincident arterial
stiffening and blunting of cardiac functional reserve, both of which
predispose to cerebral circulatory dysfunction. Given we excluded
stroke and adjusted for carotid IMT, a role for macrovascular disease
is unlikely. Microvascular disease on the other hand may be relevant in
the context of associations between LV dysfunction and white matter
hyperintensity (WMH) volume27; however, in the absence of WMH
and other microvascular indices modifying associations between dia-
stolic and cognitive function in the SABRE study,8 this would appear
an incomplete explanation.
Study limitations
Methodological drawbacks include reliance on a single screening tool
for MCI rather than comprehensive assessments of specific cognitive
domains. Since the cross-sectional design precludes causal assump-
tions, longitudinal and/or prospective trial data will be necessary to
determine the extent to which observed associations reflect mecha-
nistic links and/or common risk pathways. Given sample size require-
ments for multivariate analyses, we did not investigate whether
independent associations in the full cohort were consistent across
relevant subgroups. This also precluded adjustment for other poten-
tial MCI antecedents. Finally, it is unclear whether our findings will be
generalizable to non-ischaemic disease since coronary artery disease
represented the predominant CHF antecedent.
Conclusions
The present study points to a high burden of MCI in patients with
chronic heart disease at high-risk of CHF. This supports the conten-
tion that even subclinical cardiac disease has an adverse impact on
cognitive function. Indeed, our data indicate that the odds of MCI are
two times higher in patients with diastolic dysfunction compared to
those with normal cardiac structure/function. Further work is war-
ranted to determine the potential role of diastolic dysfunction in MCI
risk prediction and its value as a therapeutic target.
Supplementary data
Supplementary data are available at European Heart Journal—
Cardiovascular Imaging online.
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Libman–Sacks vegetations detected by 3D echocardiography
Nir Flint1,2* and Robert J. Siegel1
1Heart institute, Cedars-Sinai Medical Center, 127 S San Vincente Blvd, AHSP A3417, Los Angeles, CA 90048, USA; and 2Department of Cardiology, Tel-Aviv Sourasky
Medical Center affiliated to the Sackler Faculty of Medicine, Tel-Aviv University, 6 Weizmann st., Tel-Aviv 6423906, Israel
* Corresponding author. Tel: 11 310 423 3849; Fax: 11 310 423 4627. E-mail: nir.flint@cshs.org
A 35-year-old womanwith a history of systemic lupus erythematosus presented with symptoms of congestive heart failure. She was treated
with diuretics with resolution of her dyspnoea. Laboratory testing revealed a white-cell count of 7300/mm3, creatinine was 2.2mg/dL, and
C-reactive protein level was 10.2mg/L (normal< 5). Repeated blood cultures were negative. Transthoracic echo demonstrated thickened
mitral valve leaflets and severe mitral regurgitation. On 3D transoesophageal echocardiography, vegetations were observed on the atrial
(Panel A, arrow) as well as the ventricular aspect (Panel B, arrows) of the posterior mitral leaflet, consistent with Libman–Sacks endocarditis
(LSE).
In their 1924 seminal paper Libman and Sacks described four patients with a new form of endocarditis identified at autopsy. It was charac-
terized as ‘. . .free from demonstrable micro-organisms’, emphasizing that ‘. . .the lesions on the posterior cusp of the mitral valve were situated chiefly
on the ventricular aspect of the valve’. 2D echocardiography primarily images the atrial aspect of the mitral valve leaflets and is limited in its abil-
ity to image the valve from the ventricular side (see Supplementary data online, Videos S1 and S2). Hence LSE vegetations have been
described on echocardiography as being on the atrial surface of the mitral valve leaflets. 3D echocardiography allows the visualization of the
undersurface of the mitral valve. This enables the detection of vegetations on the ventricular aspect of the mitral valve (Panel B and
Supplementary data online, Video 3) as originally described in Libman and Sacks’ autopsy case series (Panel C, arrowheads). This patient was
discharged home for future surgical re-evaluation.
Supplementary data are available at European Heart Journal—Cardiovascular Imaging online.
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